# Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Study · id `cardio:ct-nct02042534` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02042534](<https://clinicaltrials.gov/study/NCT02042534>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02042534

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.

## Technical summary

Registry record NCT02042534. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2017-02-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 195 participants (enrolled count; ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Results first posted: 2017-02-08 (ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02042534, source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02042534-2017-02-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
- Acronym: TripleAXEL
- Condition: Ischemic Stroke
- Condition: Transient Ischemic Attack
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Asan Medical Center
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Asan Medical Center (`cardio:org-asan-medical-center`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial (`cardio:pubmed-28892526`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cdfbe35da906d1b5a340108e831f8bf8964cab044ed4c15f5d7cb759a0b2cb69
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
